Business Context and Reporting Period
This Form 8-K is a current report filed by Emerald Bioscience, Inc. (not Skye Bioscience, Inc.) on November 19, 2019. The report details the results of stockholder advisory votes on executive compensation ("Say-on-Pay") and the frequency of future votes, which were conducted via written consent on October 10, 2019.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
- Vote Outcome: Stockholders approved the advisory vote on executive compensation and recommended holding future Say-on-Pay votes every three years.
- Participation: 73,153,917 shares were voted in favor, representing approximately 54.6% of the issued and outstanding common stock.
- Effective Date: The advisory votes became effective on November 19, 2019.
- Board Action: Based on the results, the Board of Directors approved the executive compensation as disclosed in the March 14, 2019 Form 10-K and adopted a three-year cycle for future Say-on-Pay votes.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The text is limited to the procedural execution of the Dodd-Frank Act requirements regarding executive compensation votes.
Key Facts for Investor Verification
- Verify the company name is Emerald Bioscience, Inc., as the input metadata incorrectly referenced Skye Bioscience, Inc.
- Confirm the executive compensation details referenced in the approved vote are located in the Annual Report on Form 10-K filed on March 14, 2019.
- Note that the Say-on-Pay vote is non-binding advisory in nature.
- Future Say-on-Pay votes are now scheduled to occur once every three years.